| Outcome Measures: |
Primary: Incremental and total area under the Concentration-Time Curve (AUC 0-240 min), Postprandial responses of glucagon-like peptide-1 (GLP-1), -30, -15, 0, 10, 20, 30, 45, 60, 90, 120, 180, 240 min on study days 1 and 7 (meal tests start at 0 min) | Secondary: Incremental and total area under the Concentration-Time Curve (AUC 0-240 min), Postprandial responses of various other gut hormones, -30, -15, 0, 10, 20, 30, 45, 60, 90, 120, 180, 240 min on study days 1 and 7 (meal tests start at 0 min) | Other: Blood analysis, Lipids, Fasting status on study days 1 and 7|Blood analysis, Inflammatory and metabolic markers, Fasting status on study days 1 and 7|Faecal samples, Gut microbiota composition, Prior to study days 1 and 7|Blood analysis of paracetamol, Assessment of gastric emptying, -30 min to 240 min (ingestion of meal at 0 min) on study days 1 and 7|Bodyweight, Fasting state on study days 1 and 7|Indirect calorimetry, Basal metabolic rate, -30 min to 240 min (ingestion of meal at 0 min) on study days 1 and 7|Ultrasound measurements, Gall bladder volume, -30 min to 240 min (ingestion of meal at 0 min) on study days 1 and 7|Visual analog scale score, Appetite, -30 min to 240 min (ingestion of meal at 0 min) on study days 1 and 7
|
